Centaurus Financial Inc. Purchases 17,388 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Centaurus Financial Inc. boosted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 97.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,279 shares of the company's stock after acquiring an additional 17,388 shares during the period. Centaurus Financial Inc.'s holdings in Teva Pharmaceutical Industries were worth $778,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. boosted its stake in Teva Pharmaceutical Industries by 7.2% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after acquiring an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP bought a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $4,966,000. Asset Management One Co. Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after purchasing an additional 58,413 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Teva Pharmaceutical Industries by 2,018.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock worth $23,368,000 after purchasing an additional 1,045,305 shares in the last quarter. Finally, Capital Wealth Planning LLC boosted its holdings in Teva Pharmaceutical Industries by 8.8% in the fourth quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company's stock worth $5,435,000 after acquiring an additional 20,016 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

Shares of Teva Pharmaceutical Industries stock traded down $0.76 during mid-day trading on Friday, hitting $16.77. 19,852,269 shares of the stock were exchanged, compared to its average volume of 10,105,614. The company has a market capitalization of $19.01 billion, a P/E ratio of -11.57, a P/E/G ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company has a 50-day simple moving average of $15.52 and a 200 day simple moving average of $17.37.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The company had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Teva Pharmaceutical Industries's revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.48 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

TEVA has been the topic of several recent research reports. Hsbc Global Res upgraded Teva Pharmaceutical Industries to a "strong-buy" rating in a report on Monday, April 28th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Thursday, May 22nd. Bank of America raised their target price on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a report on Thursday, May 8th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the company from $21.00 to $23.00 in a report on Monday, May 12th. Finally, Truist Financial initiated coverage on Teva Pharmaceutical Industries in a report on Wednesday. They issued a "buy" rating and a $25.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $24.50.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.